The same eGFR, two different real bodies
A 50-year-old male with a serum creatinine of 1.0 mg/dL has an eGFR of 91.7 mL/min/1.73m² — but that figure is standardized to a reference body surface area of 1.73m², not the specific person's own body. A smaller-framed person with a real BSA of 1.47 m² has an absolute GFR of roughly 77.9 mL/min once de-normalized; a larger-framed person with a real BSA of 2.23 m² has an absolute GFR of roughly 118.2 mL/min — the identical 91.7 eGFR translating to meaningfully different real filtration rates.
The de-normalization: absolute GFR = eGFR × (patient's real BSA ÷ 1.73)
eGFR formulas are deliberately standardized to a 1.73m² reference BSA so that people of different sizes can be compared on the same scale — useful for staging kidney disease consistently. Multiplying back by a specific person's own real BSA, divided by that same 1.73m² reference, converts the standardized figure into an absolute filtration rate specific to that person's actual body.
Why this matters for dosing certain medications
Some medications — particularly those cleared renally at doses that scale with actual filtration capacity, like certain chemotherapy or antibiotic regimens — are dosed against absolute GFR, not the standardized per-1.73m² figure. Two patients with the identical reported eGFR and CKD stage can require meaningfully different doses once their real body size is accounted for.
Why the standardized eGFR is still the right tool for staging CKD
Staging chronic kidney disease deliberately uses the standardized, size-independent eGFR so that a diagnosis of stage G1 or G3a means the same thing for a small person and a large person alike. De-normalizing to an absolute rate is a separate, additional step for the specific cases — like dosing — where actual filtration capacity matters more than a standardized comparison. This is informational context only; medication dosing decisions must always be made by a qualified healthcare professional using the patient's full clinical picture.